Atara Biotherapeutics (NASDAQ:ATRA) Receives Buy Rating from Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $17.00 target price on the biotechnology company’s stock. A number of other analysts also recently issued reports on ATRA. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a […]
Canaccord Genuity Group reissued their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $17.00 target price on the biotechnology company’s stock. A number of other analysts also recently issued reports on ATRA. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a […]
